Baxter International (WBO:BAX) Interest Expense : €-342 Mil (TTM As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Baxter International Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Baxter International's interest expense for the three months ended in Dec. 2024 was € -96 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was €-342 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Baxter International's Operating Income for the three months ended in Dec. 2024 was € -1 Mil. Baxter International's Interest Expense for the three months ended in Dec. 2024 was € -96 Mil. Baxter International did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Baxter International Interest Expense Historical Data

The historical data trend for Baxter International's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Baxter International Interest Expense Chart

Baxter International Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

Get a 7-Day Free Trial

-125.77

-183.20

-389.87

-465.84

-389.64

Baxter International Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Interest Expense	Get a 7-Day Free Trial															-94.76	-96.62	-91.00	-95.50	-59.20

Baxter International Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-342 Mil.

Baxter International (WBO:BAX) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Baxter International's Interest Expense for the three months ended in Dec. 2024 was €-96 Mil. Its Operating Income for the three months ended in Dec. 2024 was €-1 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2024 was €10,139 Mil.

Baxter International's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

Baxter International did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Baxter International Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Baxter International Inc (WBO:BAX) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

BAX:USA BAX:Mexico 1BAX:Italy 0QK8:UK BTL:Germany BTL:Germany B1AX34:Brazil

Address

One Baxter Parkway, Deerfield, IL, USA, 60015

Website

https://www.baxter.com

Baxter International Inc offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.